“This is a period in which we are focusing on local development and regional expansion, and on the expansion of our product portfolio, actions which are targeting the transformation of our company into an important player on markets on which it is active. The financial results are in line with our expectations and were possible due to a series of investments and the expansion of retail distribution,” said Ozone Laboratories CEO Christopher Henwood.
In the first quarter of 2008, Ozone Laboratories posted a similar increase, of 28 percent. The company is active on six Eastern European markets: Romania, Bulgaria, Czech Republic, Slovakia, Hungary and Poland. Ozone Laboratories posted turnover worth €29.5 million in Romania and €75 million in the region.
Ozone owns no factory, but works with producers through manufacturing contracts. Its competitors include Terapia Ranbaxy, Zentiva and Sandoz. The local pharmaceutical market rose to €1.8 billion last year.
